INTRODUCTION
Ovarian cancer is the fifth most common cause of cancer death in women. Each year, approximately 20,000 American women are diagnosed with ovarian cancer and about 15,000 die from the disease (American Cancer Society, 2007) . Current treatment options consist of surgery followed by chemotherapy, and occasionally radiation therapy, but prognosis remains poor due to the highly metastatic potential of this disease (Piver et al., 1991) and long-term risk of tumor relapse after surgery. To improve therapeutic outcome, monoclonal antibodies specific for ovarian tumor-antigens are being developed (Schultes et al., 1998; Noujaim et al., 2001; Ehlen et al., 2005) .
One such ovarian-specific tumor antigen is MUC16, a member of the mucin family of receptors (O'Brien et al., 2001; Yin and Lloyd, 2001 ) which is over-expressed on the membrane of epithelial ovarian cancer cells. The extracellular domain of MUC16, called CA125, is shed from the tumor cell surface (Beck et al., 1998) . For many years the presence of shed CA125 in the serum has proven useful as a marker for not only the presence of ovarian cancer, but also for response to therapy and disease recurrence (Bast et al., 1983; Bast et al., 1998; Verheijen et al., 1999; Berek et al., 2008) . While the expression pattern of MUC16 has made this protein a potentially important target for antibody therapy (Harris, 2004; Nicodemus and Berek, 2005) , there is concern that shed CA125 may induce immune complex (IC) formation with therapeutic antibodies and prevent their effectiveness.
Here, we describe a novel CA125-specific antibody, named 3A5, which recognizes not a single epitope, but rather a repeated epitope within this tumor antigen. 3A5 was previously found to bind more sites per cell than an antibody that binds to a single epitope (Chen et al., 2007) . This property is hypothesized to enhance the therapeutic effectiveness of 3A5, and explains why 3A5 5 is currently a component of an antibody-drug conjugate (ADC) strategy (Trail et al., 2003; Polakis, 2005; Wu and Senter, 2005; Chen et al., 2007; Junutula et al., 2008) . This strategy consists of combining the targeting power of 3A5 with the chemotherapeutic effect of a cytotoxic drug, demonstrating potent anti-tumor activity in the OVCAR-3 ovarian tumor model (Chen et al., 2007; Junutula et al., 2008) . Due to the multi-valency of 3A5, IC formation may have a greater impact on tumor targeting and/or in vivo distribution of this antibody in comparison with antibodies binding with a lower stoichiometry. To address this potential problem, we performed studies to determine the conditions and kinetics by which IC formation between 3A5 and CA125 occurs in vitro, to explore the tissue distribution of pre-formed 3A5-CA125 IC, and to characterize the in vivo impact of circulating CA125 on 3A5 distribution to target tissues at early and late stages of the disease, using an orthotopic ovarian cancer animal tumor model.
In this model, immune-compromised mice were injected with OVCAR-3 cells, a human ovarian carcinoma cell line, directly into the peritoneal cavity. This model recapitulates ovarian cancer in human patients in aspects such as extra-pelvic extension, ascites fluid accumulation, and at later stages dissemination within the peritoneal organs. In addition, this mouse model also resembles the human disease in its heterogeneity in the levels of shed CA125 antigen in the serum and ascites (Chen et al., 2007) . Thus, this tumor model is thought to be a suitable representation of ovarian cancer in humans, providing clinically relevant information of the antitumor activity of the potential therapeutic agent.
Unlike subcutaneous xenograft models, a major challenge with this model is the quantitative assessment of drug distribution and progression of the tumor due to its localization within the organs in the peritoneum. Hence, in this study, in vivo bioluminescence imaging of luciferase-expressing OVCAR-3 (OVCAR-3/luc) tumor cells was used to allow the in vivo 6 characterization of tumor burden and quantitative whole body autoradiography (QWBA) was used to assess drug distribution; overcoming difficulties associated with the traditional tissue dissection.
In these studies, we found that the interaction of 3A5 with CA125 with results in the formation of IC in vitro. IC was also formed in vivo in the OVCAR-3 tumor model, in which the liver was identified as the major organ responsible for its uptake and clearance. IC formation did not, however, affect tumor targeting.
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MATERIALS AND METHODS
Reagents and Cell lines. The anti-MUC16 antibody (3A5) was previously described (Chen et al., 2007 precipitable. The resulting specific activity was 9.50 µCi/µg. OVCAR-3/luc cells were previously described (Chen et al., 2007) . In Vivo Studies. In all studies, mice were weighed, tagged, and housed in cages equipped with a coated wire floor to prevent animal contact with feces and urine. To prevent [ 125 I]
In Vitro
.30 mg/mL of sodium iodide 1 and 24 hours prior to dosing with the radiolabeled dosing
This article has not been copyedited and formatted. The final version may differ from this version. by dividing injected CPM with CPM/g tissue x 100. Plasma TCA precipitation was used to measure antibody-bound radioactivity in circulation. Briefly, the precipitated radioactivity present in 20 µL of plasma was prepared by adding 200 µL of ice-cold 1% bovine serum albumin in PBS (pH 7.2) to each plasma sample and vortex mixing, followed by the addition of 500 µL of ice-cold 20% TCA and vortex mixing again. After 30 minutes of incubation on wet ice, the samples were centrifuged at 14,000 rpm for 5 minutes. The supernatant was aspirated, and the radioactivity in the pellet of each sample was quantified for 1 minute using the gamma counter. The radioactivity before and after TCA precipitation (x 100) was used to determine the percentage of antibody-bound radioactivity for each plasma sample. using the whole-body cryosectioning technique developed by Ullberg and Larsson (Ullberg and Larsson, 1981) . QWBA allowed for the tissue distribution assessment of the test antibodies avoiding the challenge of tissue dissection where tumors grow within the normal organs.
Impact of circulating CA125 on
Animals were embedded in 4% carboxymethylcellulose and stored at -70°C until sectioning.
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This article has not been copyedited and formatted. The final version may differ from this version. Research Inc., ON, Canada) was used to quantify the concentrations of radioactivity in the calibration standards and tissues of whole-body sections, as described by Potchoiba et al. (Potchoiba et al., 1995) for [ 14 C] xenobiotics. The quantitation method described here was demonstrated to be as accurate and precise as the values obtained from gamma or liquid scintillation counter methods (Potchoiba et al., 1995; Potchoiba et al., 1998; Busch et al., 2000; Steinke et al., 2000) . The lower limit of quantification was determined by the lower detected concentration in the calibration standards (0.01 µCi/mL). The concentration of radioactivity from tissues was extrapolated from each standard curve as µCi/g of tissue, assuming that 1 g of tissue weight was equivalent to 1 mL, and converted to a percent of the injected dose. The [ 125 I] associated antibodies distributed equally to ascites and solid tumors; therefore both compartments were added together during the quantitation and are reported as ascites-tumor values.
This article has not been copyedited and formatted. The final version may differ from this version. (Bast et al., 1983) . Thus, as represented in Figure 1A , CA125 at a fixed concentration of 1000 U/mL was incubated for 24 hours at 37°C, according to Haisma et al (Haisma et al., 1987) , with increasing concentrations of [ 125 I] 3A5 (0.1, 0.5, and 1 µg/mL). After incubation, samples were analyzed by SEC-HPLC to determine the extent of IC formation. At a fixed CA125 concentration of 1000 U/mL, the addition of 0.1 ug/mL of [ 125 I] 3A5 resulted in approximately 40% of the antibody forming IC (Fig. 1A) . As the antibody concentration was increased relative to CA125, the proportion of IC formation relative to the total antibody decreased (Fig. 1A) . Similarly, when the [ 125 I] 3A5 concentration was fixed at 0.1 µg/mL in the presence of varying concentrations of CA125, IC formation was concentration dependent such that the percent of free 3A5 decreased with increasing CA125 antigen (Fig. 1B) . In these studies, a CA125 concentration of 1000 U/mL with 0.1 µg/mL of 3A5 resulted in 40-60% of the antibody formed ICs by 24 hours (Figs. 1A, 1B) . Therefore, this concentration of CA125 and 3A5 was used to determine the kinetics of IC formation in vitro over 0, 0.5, 4, and 24 hours. The formation of ICs was rapid, with 80% of the total IC formation occurring within the first 0.5 hours (Fig. 1C) . These data indicate that the proportion of IC formed between 3A5 and CA125 is dependent on the relative concentrations of the antigen and antibody. IC formation is enhanced when the concentration of CA125 is greater than that of 3A5. confirmed that 10% of the 3A5 was present as IC (Fig 2A, left panel) , as predicted from in vitro data (Fig. 1B) . No IC was present in the control group dosing material (Fig 2A, right panel Overall, in both groups the highest %ID/g was observed in the blood and highly perfused organs (spleen>lungs>liver>kidney>heart), indicating equilibration between the blood and other normal tissues, resulting in a parallel decrease with blood concentrations (Fig. 2C) .
Impact of circulating CA125 on 3A5 tissue distribution.
Early stage of ascites and tumor development. To explore whether tumors that shed CA125 would result in IC formation and alteration of the tissue distribution of 3A5, OVCAR-3/luc tumor cells were inoculated into mice (Chen et al., 2007) . A model at an early stage of
This article has not been copyedited and formatted. The final version may differ from this version. In tumor-bearing mice, 8% of 3A5-related radioactivity was present as IC in plasma at 0.25 hours post-dose (Fig. 3A) . At 8 hours post-dose, the products of IC degradation were detected in plasma, as evidenced by the presence of a lower molecular weight peak in SEC-HPLC. By 24 and 48 hours post-dose, plasma radioactivity was diminished to below the levels of detection. In contrast, plasma from non-tumor-bearing mice showed no evidence of IC formation at any time point and radioactivity clearance was slower than that of tumor-bearing mice (Fig.   3B ).
To further characterize the in vivo catabolism of [ 125 I] 3A5 in plasma over the time course of the study, TCA precipitation was performed on plasma samples from tumor-bearing and nontumor-bearing mice collected at terminal time points. In both groups, [ 125 I] 3A5 was approximately 100% precipitable at all time points (Fig. 3C and D) , with the exception of the 8 hour post-dose samples from tumor-bearing mice where the percentage of precipitable radioactivity declined to 75%. These data are consistent with the degradation products observed by SEC-HPLC at 8 hours post-dose in these mice (Fig. 3A) .
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Ascites-tumor uptake of [ 125 I] 3A5 increased until 8 hours post-dose, and remained unchanged over the 48 hour time course of the study (Fig. 4B, inset) .
In non-tumor-bearing mice, radioactivity was largely distributed in the blood. After equilibration with highly perfused organs (spleen > lungs > liver > kidney = bone marrow > heart), levels in the blood and tissues remained relatively sustained over the 24 hours post-dose ( Fig. 4C and D) . by tumor efficacy studies of a 3A5 ADC (Chen et al., 2007) , was administered to mice bearing OVCAR-3/luc tumors. Following the IV bolus administration neither IC formation nor degradation products were detected in plasma at any time point as determined by SEC-HPLC and TCA precipitation ( Fig. 5A and inset, respectively). QWBA assessment of [ 125 I] 3A5 tissue distribution in tumor-bearing mice is depicted in Fig. 5B and C, with data represented as %ID/g in Fig. 5C . These experiments revealed high radioactivity levels in the blood and highly perfused organs. Radioactivity levels in these normal tissues decreased in parallel with blood radioactivity. In contrast, the %ID/g in ascites-tumor increased by 8 hours post-dose and remained relatively unchanged over the remaining time-course of the study ( Fig. 5B and C) .
To determine the specificity of 3A5 uptake by ascites-tumor, the distribution of 3A5 distribution was compared with that of an isotype control antibody in tumor-bearing mice. Mice bearing OVCAR-3/luc tumors at a late stage of the disease were dosed with [ 125 I] anti-gD (isotype control antibody) + unlabeled anti-gD for a total dose of 3.5 mg/kg. Tissue-to-blood ratios, a measure of tissue-specific uptake, were calculated from mice dosed with isotype control or 3A5 antibody ( Fig. 6A and B, respectively) . A ratio >1, indicative of the specific uptake of an antibody by a tissue, was only observed at 120 hours in the ascites-tumor (8.85±1.04) of mice dosed with 3A5 (Fig. 6B) , while ascites-tumor from the control antibody revealed ratios <1 (Fig.   6A ). All normal tissues from 3A5 and control antibody had ratios < 1 at all time points (Fig. 6 ).
DISCUSSION
In recent years, therapeutic antibodies have been used to specifically target tumor cells based on their surface expression of unique antigens. In some cases, the antigen is shed from the cell surface into the circulation where the antibody may form ICs with the circulating antigen, potentially impacting therapeutic efficacy by preventing it from reaching the tumor, and/or altering the antibody kinetics of distribution and clearance (Bruno et al., 2005) . A number of ovarian cancer pre-clinical and clinical studies have addressed the potential risks of shed antigen (Hagan et al., 1985; Haisma et al., 1987; Pimm et al., 1989; Kobayashi et al., 1993; Pimm, 1995; Sakahara et al., 1996; Davies et al., 1997; McQuarrie et al., 1997; Prinssen, 1998; Maeda et al., 2004) . In ovarian cancer patients, IC formation was detected upon delivery of an anti-CA125
antibody. However, the effect of circulating CA125 antigen did not appear to compromise pharmacokinetics of the antibody when it was used in excess of the circulating antigen (Sakahara et al., 1996; McQuarrie et al., 1997 ).
Here we studied 3A5, a novel antibody (Chen et al., 2007) which binds to a repeated epitope on CA125, and is currently a component of an antibody-drug conjugate strategy for the treatment of epithelial ovarian cancer (Chen et al., 2007) . Due to the avidity of 3A5 to CA125, IC formation could impact the delivery of the antibody to the tumors and induce unwanted toxicities in normal tissues. To address this, we performed a series of studies to assess IC formation in vitro and in vivo, as well as to characterize the impact of 3A5-CA125 interaction on the kinetics of 3A5 distribution.
We demonstrated that the in vitro interaction between proportional increase in IC formation (Fig. 1) . Importantly, when the concentration of 3A5 was increased while that of the antigen was held constant, the proportion of IC was low relative to the total 3A5. The in vitro kinetics of IC formation was rapid, in line with that reported by Haisma et al (Haisma et al., 1987) . Consistently, IC formation between 3A5 and circulating CA125 was detected in vivo in tumor-bearing mice only at low concentrations of the antibody relative to the antigen, which was determined by ELISA. When mice presenting with clinically relevant CA125 levels (69-318 U/mL) (Bast et al., 1983) , were given a therapeutic dose of 3A5 (3.5 mg/kg) (Chen et al., 2007) no IC was detected. Collectively, these data suggest that IC formation at therapeutic 3A5 concentrations appears to consume a small fraction of the total 3A5. Further, whether ICs were administered pre-formed to normal mice, or formed in vivo in tumor-bearing mice, they were rapidly cleared from circulation, with the liver demonstrating a major role in the uptake, and degradation. Consistent with liver catabolism, there was evidence of IC degradation products in the plasma, the contents of the intestines, and the stomach, an organ known to absorb free [ 125 I] (Regoeczi, 1987) . Aside from the liver, we observed no overall difference in tissue kinetics in normal mice dosed with either 3A5-CA125 IC pre-formed in vitro, or 3A5 alone (Fig.   2C ). However, when IC was formed in vivo by administering a low dose of 3A5 (75 µg/kg) to tumor bearing mice, faster clearance of the antibody was observed in normal tissues of these mice when compared to 3A5 dosed to normal mice (Figs. 4A and B) . This effect was not as pronounced when tumor-bearing mice received a therapeutically relevant dose of 3A5 (3.5 mg/kg) ( Fig. 5B and C ).
An important finding in these studies was that 3A5 distribution to the tumor was achieved despite IC formation. At the therapeutic dose of 3A5, persistent uptake of antibody in ascitestumors was observed, with no IC detected and no uptake or accumulation in normal tissues.
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The data herein describe the circumstances under which IC forms in vitro and in vivo. In conclusion, the interaction between 3A5 and CA125 resulted in the formation of ICs that were rapidly distributed from circulation to the liver. At a therapeutically relevant dose, however, the proportion of IC relative to total 3A5 appeared to be minor, with a consequent greater distribution of uncomplexed 3A5 to the tumor. As a point of consideration, it remains possible that as the concentration of 3A5 decreases in vivo due to normal clearance, conditions may arise that result in a proportional increase in IC formation, a phenomenon that should be monitored clinically.
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